Human neutrophil priming: chemiluminescence modified by hydroxyapatite and three bisphosphonates in vitro.

P. M. Hyvönen, Michael Kowolik

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Activated inflammatory cells, particularly neutrophil granulocytes, are thought to play an important role in the tissue damage associated with several chronic inflammatory diseases including rheumatoid arthritis. Of importance to pathogenesis may be the interaction of cells and hydroxyapatite (HA) crystals, both present in synovial fluid, and to therapy, the ameliorating influence of many groups of drugs, including the bisphosphonates. The aim of this in vitro study was to verify the priming effect of serum-coated HA particles on human neutrophils, and investigate possible modification by three bisphosphonates in current clinical use; clodronate, etidronate, and pamidronate. After incubation of neutrophils with drugs alone, HA or drug/HA combinations over a bisphosphonate concentration range of 1.10(-5) to 1.10(5) micrograms/ml, for 60 or 270 min, resultant luminol-dependent chemiluminescence (CL) was monitored as millivoltage after further challenge with serum-treated zymosan. As previously shown, HA produced a profound priming to the second challenge and this was not appreciably altered by the drugs bound to HA, except at the highest concentrations. Pamidronate, in particular, appeared to sustain the cell activity even at these high concentrations, well beyond the tissue levels achieved in clinical therapeutics. Only at highest concentrations of 1.10(3) and 1.10(5) micrograms/ml did the drugs alone inhibit cellular activity, when challenged with zymosan. This study therefore, confirmed the ability of HA particles to strongly prime human neutrophils and the low toxicity of the three bisphosphonates tested within this cell model.

Original languageEnglish (US)
Pages (from-to)69-76
Number of pages8
JournalJournal of Clinical and Laboratory Immunology
Volume40
Issue number2
StatePublished - 1993
Externally publishedYes

Fingerprint

Diphosphonates
Durapatite
Luminescence
Neutrophils
pamidronate
Zymosan
Pharmaceutical Preparations
Etidronic Acid
Clodronic Acid
Luminol
Fluid Therapy
Synovial Fluid
Drug Combinations
In Vitro Techniques
Serum
Granulocytes
Cell Communication
Rheumatoid Arthritis
Chronic Disease

ASJC Scopus subject areas

  • Immunology

Cite this

@article{446d5717042b411e8990c102d90300bf,
title = "Human neutrophil priming: chemiluminescence modified by hydroxyapatite and three bisphosphonates in vitro.",
abstract = "Activated inflammatory cells, particularly neutrophil granulocytes, are thought to play an important role in the tissue damage associated with several chronic inflammatory diseases including rheumatoid arthritis. Of importance to pathogenesis may be the interaction of cells and hydroxyapatite (HA) crystals, both present in synovial fluid, and to therapy, the ameliorating influence of many groups of drugs, including the bisphosphonates. The aim of this in vitro study was to verify the priming effect of serum-coated HA particles on human neutrophils, and investigate possible modification by three bisphosphonates in current clinical use; clodronate, etidronate, and pamidronate. After incubation of neutrophils with drugs alone, HA or drug/HA combinations over a bisphosphonate concentration range of 1.10(-5) to 1.10(5) micrograms/ml, for 60 or 270 min, resultant luminol-dependent chemiluminescence (CL) was monitored as millivoltage after further challenge with serum-treated zymosan. As previously shown, HA produced a profound priming to the second challenge and this was not appreciably altered by the drugs bound to HA, except at the highest concentrations. Pamidronate, in particular, appeared to sustain the cell activity even at these high concentrations, well beyond the tissue levels achieved in clinical therapeutics. Only at highest concentrations of 1.10(3) and 1.10(5) micrograms/ml did the drugs alone inhibit cellular activity, when challenged with zymosan. This study therefore, confirmed the ability of HA particles to strongly prime human neutrophils and the low toxicity of the three bisphosphonates tested within this cell model.",
author = "Hyv{\"o}nen, {P. M.} and Michael Kowolik",
year = "1993",
language = "English (US)",
volume = "40",
pages = "69--76",
journal = "Journal of Clinical and Laboratory Immunology",
issn = "0141-2760",
publisher = "Teviot Scientific Publications Ltd.",
number = "2",

}

TY - JOUR

T1 - Human neutrophil priming

T2 - chemiluminescence modified by hydroxyapatite and three bisphosphonates in vitro.

AU - Hyvönen, P. M.

AU - Kowolik, Michael

PY - 1993

Y1 - 1993

N2 - Activated inflammatory cells, particularly neutrophil granulocytes, are thought to play an important role in the tissue damage associated with several chronic inflammatory diseases including rheumatoid arthritis. Of importance to pathogenesis may be the interaction of cells and hydroxyapatite (HA) crystals, both present in synovial fluid, and to therapy, the ameliorating influence of many groups of drugs, including the bisphosphonates. The aim of this in vitro study was to verify the priming effect of serum-coated HA particles on human neutrophils, and investigate possible modification by three bisphosphonates in current clinical use; clodronate, etidronate, and pamidronate. After incubation of neutrophils with drugs alone, HA or drug/HA combinations over a bisphosphonate concentration range of 1.10(-5) to 1.10(5) micrograms/ml, for 60 or 270 min, resultant luminol-dependent chemiluminescence (CL) was monitored as millivoltage after further challenge with serum-treated zymosan. As previously shown, HA produced a profound priming to the second challenge and this was not appreciably altered by the drugs bound to HA, except at the highest concentrations. Pamidronate, in particular, appeared to sustain the cell activity even at these high concentrations, well beyond the tissue levels achieved in clinical therapeutics. Only at highest concentrations of 1.10(3) and 1.10(5) micrograms/ml did the drugs alone inhibit cellular activity, when challenged with zymosan. This study therefore, confirmed the ability of HA particles to strongly prime human neutrophils and the low toxicity of the three bisphosphonates tested within this cell model.

AB - Activated inflammatory cells, particularly neutrophil granulocytes, are thought to play an important role in the tissue damage associated with several chronic inflammatory diseases including rheumatoid arthritis. Of importance to pathogenesis may be the interaction of cells and hydroxyapatite (HA) crystals, both present in synovial fluid, and to therapy, the ameliorating influence of many groups of drugs, including the bisphosphonates. The aim of this in vitro study was to verify the priming effect of serum-coated HA particles on human neutrophils, and investigate possible modification by three bisphosphonates in current clinical use; clodronate, etidronate, and pamidronate. After incubation of neutrophils with drugs alone, HA or drug/HA combinations over a bisphosphonate concentration range of 1.10(-5) to 1.10(5) micrograms/ml, for 60 or 270 min, resultant luminol-dependent chemiluminescence (CL) was monitored as millivoltage after further challenge with serum-treated zymosan. As previously shown, HA produced a profound priming to the second challenge and this was not appreciably altered by the drugs bound to HA, except at the highest concentrations. Pamidronate, in particular, appeared to sustain the cell activity even at these high concentrations, well beyond the tissue levels achieved in clinical therapeutics. Only at highest concentrations of 1.10(3) and 1.10(5) micrograms/ml did the drugs alone inhibit cellular activity, when challenged with zymosan. This study therefore, confirmed the ability of HA particles to strongly prime human neutrophils and the low toxicity of the three bisphosphonates tested within this cell model.

UR - http://www.scopus.com/inward/record.url?scp=0027792850&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027792850&partnerID=8YFLogxK

M3 - Article

C2 - 7932630

AN - SCOPUS:0027792850

VL - 40

SP - 69

EP - 76

JO - Journal of Clinical and Laboratory Immunology

JF - Journal of Clinical and Laboratory Immunology

SN - 0141-2760

IS - 2

ER -